Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: A combined study of two cohorts

  title={Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: A combined study of two cohorts},
  author={Lucette A. Cysique and Paul Maruff and Bruce J. Brew},
  journal={Journal of NeuroVirology},
The objective of this study was to assess the prevalence and pattern of neuropsychological impairment in cohorts of human immunodeficiency virus (HIV)-infected individuals across pre- and post-HAART (highly active antiretroviral therapy) eras. Two cohorts of HIV-infected individuals attending tertiary referral hospital outpatient clinics were studied. The cohorts represented two eras of antiretroviral medication: monotherapy (n = 51) and HAART (n = 90). Each was compared in nine… 

Figures and Tables from this paper

Prevalence of human immunodeficiency virus-associated cognitive impairment in a group of Hispanic women at risk for neurological impairment

The findings should enhance awareness of the prevalence of HIV-associated cognitive impairment, both clinically apparent and “asymptomatic,” in Hispanic women and lead to improvements in areas such as education and compliance and to reevaluation of treatment interventions.

A study of neuropsychological profile of human immunodeficiency virus-positive children and adolescents on antiretroviral therapy

The findings show that HIV infection is associated with significant cognitive and functional impairment and the role of ART in these impairments requires further study.

Differential Diagnosis of HIV-Associated Neurocognitive Disorders

Cognitive dysfunction after the recent commencement of HAART suggests an immune reconstitution inflammatory syndrome (IRIS) related to a previously subclinical opportunistic infection, most commonly progressive multifocal leukoencephalopathy, but HAND as an IRIS phenomenon directly related to HIV is also a possibility.

Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients

HAND was associated with efavirenz use, suggesting the potential neurotoxicity of this drug, and routine neuropsychological examinations could help clinicians make correct diagnoses and manage mild, but clinically relevant, forms of HAND.

Prevalence of non-confounded HIV-associated neurocognitive impairment in the context of plasma HIV RNA suppression

Despite suppression of systemic viral load, non-confounded HIV-related NP-impairment prevalence reached 18.1%.

Interruptions of antiretroviral therapy in human immunodeficiency virus infection: are they detrimental to neurocognitive functioning?

A higher prevalence of neurocognitive impairment was detected in HIV-infected persons who had interrupted antiretroviral therapy in the past, and neuroc cognitive functioning was observed to be more impaired in the same individuals.

High prevalence of HIV-associated neurocognitive disorder in HIV-infected patients with a baseline CD4 count ≤ 350 cells/μL in Shanghai, China.

It is found that HAND frequently developed in HIV-infected patients with a baseline CD4 count ≤ 350 cells/μL in Shanghai, China and should be routinely screened for in all newly diagnosed HIV-positive patients, and especially in those with the aforementioned risk factors.

HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors

High rates of mild NCI persist at all stages of HIV infection, despite improved viral suppression and immune reconstitution with CART, and the consistent association of NCI with nadir CD4 across eras suggests that earlier treatment to prevent severe immunosuppression may also help prevent HAND.

HIV-Associated Neurological Disorders

Although HAART has a profound impact on the incidence and severity of HAND, there exists a ‘therapeutic gap’ as even HAART that is effective at inducing durable virological suppression may only partially reverse HAND and there may be potential CNS adverse effects of antiretroviral agents.



Highly active antiretroviral treatment in HIV infection: benefits for neuropsychological function

Findings suggest that HAART benefits neuropsychological function through the reduction of viral load, and those without neuropsychologically impairment had significantly lower mean viral load levels and were more likely to have undetectable viral load than those with impairment.

Antiretroviral therapy in HIV infection: are neurologically active drugs important?

No direct benefit of neuroactive HAART therapy was found in patients with advanced human immunodeficiency virus infection, however, in neuropsychologically impaired patients, there was a benefit in memory function, suggesting that a threshold of neuropsychological impairment is required for the benefit of NeuroactiveHAART.

HIV-associated cognitive impairment before and after the advent of combination therapy

Even though HAART has reduced the incidence of HIV dementia, HIV-associated cognitive impairment continues to be a major clinical problem among individuals with advanced infection.

Psychomotor slowing in HIV infection: a predictor of dementia, AIDS and death.

A brief neuropsychological test battery may be useful for early detection of HIV+ individuals with a poorer prognosis who may benefit from more aggressive treatment to prevent HIV dementia.

Outcome of patients with HIV-1-related cognitive impairment on highly active antiretroviral therapy

Despite a 25% mortality rate among patients who had cognitive impairment at their first NP examination, GEE showed a positive relationship between the duration of HAART and cognitive performance and distinguishes neuropathological mechanisms appear to underlie psychomotor and memory dysfunctions in AIDS.

Attenuated central nervous system infection in advanced HIV/AIDS with combination antiretroviral therapy.

Plasma levels of monocyte chemotactic protein type 1 and tumor necrosis factor alpha correlated weakly with HIV RNA levels but did not distinguish those with neurological deficits, and in CART users, CSF HIV RNA and immune activation markers may fail to discriminate milder degrees of HIV-D and MCMD.

Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome

Elevated CSF HIV‐1 RNA levels in NP impaired subjects with AIDS are found, suggesting that systemic viral replication, possibly through CD4+ mononuclear cell trafficking, may govern virus levels in CSF, whereas in AIDS, CD4 cell depletion may unmask a correlation between increased productive central nervous system HIV infection and clinical neurocognitive disorders.

Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment.

HAART produces a positive and sustained effect on neurocognitive impairment in HIV-infected patients and a reduction of plasma viral load was associated with the regression of neuropsychological test abnormalities.

Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients

A negative interaction between virological response and the duration of antiretroviral treatment suggests long-term selection of drug-resistant CSF HIV-1 strains.

HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy.

Although combination therapies decrease overall mortality and prevalence of CNS opportunistic infections, these therapies may be less active in preventing direct HIV-1 effects on the brain.